OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis $0.03 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0452-Week Range$0.02▼$0.05Volume208,290 shsAverage Volume72,974 shsMarket Capitalization$11.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Oncotelic Therapeutics alerts: Email Address Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.Read More OTLC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLC Stock News HeadlinesJune 11, 2024 | globenewswire.comONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGYMay 30, 2024 | globenewswire.comONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETINGJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 20, 2024 | globenewswire.comONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETINGMay 19, 2024 | morningstar.comOncotelic Therapeutics Inc OTLCMay 16, 2024 | finance.yahoo.comONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024March 25, 2024 | finance.yahoo.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 25, 2024 | globenewswire.comLinkage of Cancer and Lupus in Gliomas PatientsJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...March 4, 2024 | globenewswire.comInvitation to Participate in STOP-PC Clinical TrialFebruary 22, 2024 | benzinga.comOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning CallsFebruary 3, 2024 | msn.comOncotelic Therapeutics Strikes Material Definitive Legal AgreementJanuary 23, 2024 | morningstar.comLineage Cell Therapeutics Inc LCTXDecember 18, 2023 | finance.yahoo.comOncotelic Therapeutics Announces Opening of GMP Manufacturing PlantNovember 15, 2023 | finanznachrichten.deOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsNovember 15, 2023 | msn.comOncotelic Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comOncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The ChargeSee More Headlines Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/19/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OTLC CUSIPN/A CIK908259 Webwww.mateon.com Phone(650) 635-7000Fax650-635-7001Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,900,000.00 Net MarginsN/A Pretax Margin-11,535.72% Return on Equity-65.10% Return on Assets-25.41% Debt Debt-to-Equity Ratio0.20 Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual Sales$70,000.00 Price / Sales162.51 Cash Flow$0.01 per share Price / Cash Flow2.20 Book Value$0.03 per share Price / Book0.93Miscellaneous Outstanding Shares406,270,000Free Float246,931,000Market Cap$11.38 million OptionableNot Optionable Beta-0.20 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Vuong Trieu Ph.D. (Age 61)Chairman & CEO Mr. Amit Shah (Age 57)Chief Financial Officer Dr. Anthony E. Maida III (Age 72)B.A., MA, MBA, Ph.D., Chief Medical Officer Translation Medicine & Director Mr. Saranjit Saund (Age 66)CBO & GM of AI Division Mr. Steven W. King (Age 60)Consultant & Director Dr. Larn Hwang (Age 61)Chief Scientific Officer Dr. Seymour Howard Fein M.D. (Age 75)Chief Regulatory Officer & Chief Medical Officer Mr. Burcak BeserCTO of AI DivisionMore ExecutivesKey CompetitorsBarinthus BiotherapeuticsNASDAQ:BRNSVaccitechNASDAQ:VACCRallybioNASDAQ:RLYBImmix BiopharmaNASDAQ:IMMXOcuphire PharmaNASDAQ:OCUPView All Competitors OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed this year? Oncotelic Therapeutics' stock was trading at $0.0383 on January 1st, 2024. Since then, OTLC shares have decreased by 26.9% and is now trading at $0.0280. View the best growth stocks for 2024 here. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OTLC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncotelic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
